Outils pour la prédiction de la réponse tumorale et des tissus sains en oncologie radiothérapie

Autor: Pascal Fenoglietto, O. Riou, Florence Castan, D. Azria, F. Bons, Muriel Brengues, N. Bonnefoi, Céline Bourgier, Mahmut Ozsahin, Sophie Gourgou, R. Draghici, M.-P. Farcy-Jacquet, Henri-Alexandre Michaud

Publikováno v: Cancer Radiothérapie
Cancer Radiothérapie, Elsevier Masson, 2019, 23, pp.666-673. ⟨10.1016/j.canrad.2019.07.152⟩
Cancer/Radiothérapie
Cancer/Radiothérapie, Elsevier Masson, 2019, 23, pp.666-673. ⟨10.1016/j.canrad.2019.07.152⟩

The impact of curative radiotherapy depends mainly on the total dose delivered homogenously in the target volume. Tumor sensitivity to radiotherapy may be particularly inconstant depending on location, histology, somatic genetic parameters and the ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89eb34c5bc839e3bc7c855db008df93e
https://hal.archives-ouvertes.fr/hal-03487486

[Predictive assays for responses of tumors and normal tissues in radiation oncology]

Autor: O, Riou, C, Bourgier, M, Brengues, N, Bonnefoi, H-A, Michaud, F, Castan, S, Gourgou, R, Draghici, M-P, Farcy-Jacquet, F, Bons, P, Fenoglietto, M, Ozsahin, D, Azria

Publikováno v: Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. 23(6-7)

The impact of curative radiotherapy depends mainly on the total dose delivered homogenously in the target volume. Tumor sensitivity to radiotherapy may be particularly inconstant depending on location, histology, somatic genetic parameters and the ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c07a33fb175633871e4e7f22835aec29
https://pubmed.ncbi.nlm.nih.gov/31451357

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Autor: Xavier Pivot, Gilles Romieu, Marc Debled, Jean-Yves Pierga, Pierre Kerbrat, Thomas Bachelot, Alain Lortholary, Marc Espié, Pierre Fumoleau, Daniel Serin, Jean-Philippe Jacquin, Christelle Jouannaud, Maria Rios, Sophie Abadie-Lacourtoisie, Laurence Venat-Bouvet, Laurent Cany, Stéphanie Catala, David Khayat, Laetitia Gambotti, Iris Pauporté, Celine Faure-Mercier, Sophie Paget-Bailly, Julie Henriques, Jean Marie Grouin, C Piprot, L Cals, L Chaigneau, F Demarchi, T N'Guyen, U Stein, C Villanueva, JL Bréau, AK Chouahnia, P Saintigny, F Boué, P deSaint-Hilaire, I Guimont, N Grossat, B Valenza, E Lévy, J Médioni, C Delbaldo, J Grenier, D Pouessel, S Lavau-Denès, C Falandry, C Fournel-Fédérico, G Freyer, S Tartas, V Trillet-Lenoir, F Bons, G Auclerc, S Chièze, N Raban, C Tournigand, S Trager-Maury, G Bousquet, C Cuvier, S Giacchetti, A Hocini, C LeMaignan, JL Misset, D Avenin, C Beerblock, J Gligorov, P Rivera, H Roché, P Bougnoux, N Hajjaji, O Capitain, R Delva, P Maillart, P Soulié, H Bonnefoi, M Durand, N Madranges, L Mauriac, P Chollet, AF Dillies, X Durando, JP Ferrière, C Mouret-Reynier, JM Nabholtz, I Van Praagh, P Cottu, V Diéras, A Durieux, M Galotte, V Girre, S Henry, I Iurisci, M Jouve, V Laurence, L Mignot, S Piperno-Neumann, P Tresca, B Coudert, E Ferrant, F Mayer, AC Vanneuville, J Bonneterre, V Servent, L Vanlemmens, P Vennin, JP Guastalla, P Biron, L Dupuy-Brousseau, L Lancry, I Ray-Coquard, P Rebattu, O Trédan, JM Extra, F Rousseau, C Tarpin, M Fabbro, E Luporsi, L Uwer, B Weber, D Berton-Rigaud, E Bourbouloux, M Campone, JM Ferrero, P Follana, R Largillier, V Mari, B Costa, H Curé, JC Eymard, N Jovenin, D Lebrun, J Meunier, G Yazbek, D Gedoin, B Laguerre, C Lefeuvre, E Vauléon, A Chevrier, C Guillemet, M Leheurteur, O Rigal, I Tennevet, C Veyret, E Brain, M Guiterrez, F Mefti-Lacheraf, T Petit, F Dalenc, L Gladieff, F André, S Delaloge, J Domont, J Ezenfis, M Spielmann, P Guillet, V Boulanger, J Provençal, L Stefani, C Alliot, D Ré, C Bellaiche-Miccio, G Boutan-Laroze, R Vanica, P Dion, G Sadki-Benaoudia, A Marti, AL Villing, B Slama, JL Dutel, S Nguyen, R Saad, O Arsène, Z Merad-Boudia, H Orfeuvre, J Egreteau, MJ Goudier, R Lamy, B Leduc, C Sarda, B Salles, C Agostini, I Cauvin, A Dufresne, M Mangold, S Lebouvier-Sadot, B Audhuy, JC Barats, S Cluet-Dennetière, D Zylberait, G Netter, L Gautier-Felizot, I Cojean-Zelek, A Plantade, S Vignot, E Guardiola, P Marti, I deHartingh, R Diab, A Dietmann, S Ruck, C Portois, S Oddou-Lagranière, F Campos-Gazeau, A Bourcier, F Priou, JF Geay, D Mayeur, P Gabez, R ElAmarti, M Combe, P Raichon-Patru, P Amsalhem, J Dauba, D Paraiso, F Guinet, B Duvert, M Litor, F Kara-Slimane, A Bichoffe, N Denizon, P Soyer, F Morvan, S Van-Hulst, L Vincent, C Alleaume, P Ibanez-Martin, A Youssef, Z Tadrist, E Carola, C Pourny, JF Toccanier, N Al-Aukla, K Mahour-Bacha, J Salvat, P Nouyrigat, S Clippe, MC Gouttebel, L Vedrine, G Clavreul, O Collard, D Mille, Y Goubely, R Hervé, S Kirscher, F Plat, V Delecroix, V Ligeza-Poisson, D Coeffic, D Fric, C Garnier, C Leyronnas, T Kreitman, E Teissier, P Martin, S Rohart deCordoue, C ElKouri, JF Ramée, C Laporte, O Bernard, T Altwegg, A Darut-Jouve, JP Dujols, F Darloy, C Giraud, V Pottier-Kyndt, N Achour, S Drony, M Moriceau, C Sarrazin, JC Legueul, J Mandet, D Besson, AC Hardy-Bessard, J Cretin, P Houyau, E Achille, D Genêt, H Thévenot, A Moran-Ribon, JM Pavlovitch, P Ardisson, I Moullet, B Couderc, V Fichet, F Burki, A Auliard, CB Levaché, P Cailleux, F Schaeffer, N Albin, D Sévin-Robiche, J Domas, S Ellis, P Montcuquet, GA Baumont, M Bégue, S Gréget, JL Ratoanina, A Vanoli, C Bielsa, M Bonichon-Lamichhane, D Jaubert, H Laharie-Mineur, L Alcaraz, E Legouffe, H Bourgeois, G Cartron, F Denis, O Dupuis, G Ganem, S Roche-Forestier, L Delzenne, E Chirat, JL Baticle, E Béguier, S Jacquot, E Janssen, H Lauché, A LeRol, JP Chantelard, GA L'Helgoualc'h, EC Antoine, A Kanoui, JF Llory, JM Vannetzel, J Vignoud, C Bruna, T Facchini, K Moutel-Corviole, A Voloch, A Ghoul, D Loiseau, N Barbet, N Dohollou, K Yakendji

Publikováno v: Lancet (London, England). 393(10191)

Summary Background In 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy with Reduced Exposure (PHARE) trial could not show that 6 months of adjuvant trastuzumab was non-inferior to 12 months. Here, we report the planned fin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a38de46b67775457b35c99536d038418
https://pubmed.ncbi.nlm.nih.gov/31178155

51. Comparison of ORL and prostate VMAT treatment plans verifications by ArcCheck® Sun Nuclear™ 3D detector and Varian™ PDIP® module: assessment of the errors detection sensitivity and the capability of each process

Autor: L. Meger, G. Moliner, K. Alric, L. Sorrol, C. Debrigode, M. Casas, M. Biancardi, R. Verstraet, K. Dubois, F. Bons, P.A. Daviau

Publikováno v: Physica Medica. 44:25

Introduction The complexity of intensity modulation radiation requires a planned dose distribution verification prior treatment. Delivery a patient treatment plan quality assurance can be carried out by EPID, 2D/3D detector or by ionization chamber.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::aa9b98e776175161d881fb31b638797a
https://doi.org/10.1016/j.ejmp.2017.10.076

Traitement des cancers volumineux du col utérin de stades I et II

Autor: L. Panel, R. de Tayrac, Pierre Marès, C. Debrigode, F. Bons, C. Ferrer, D. Dupaigne

Publikováno v: EMC - Gynécologie. 2:1-13

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::877f0468f8f1e8abbfd70f8d3f87741b
https://doi.org/10.1016/s0246-1064(07)45873-x